Evidence-Based Reviews

Cannabidiol for psychosis: A review of 4 studies

Author and Disclosure Information

 

References

Conflicting data highlights the need for longer, larger studies

Research findings on the use of CBD for psychotic symptoms in patients with schizophrenia have been conflicting. Some early research suggests that taking CBD 4 times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic amisulpride. However, other early research suggests that taking CBD for 14 days is not beneficial. The conflicting results might be related to the CBD dose used and duration of treatment.

Davies and Bhattacharya12 recently reviewed evidence regarding the efficacy of CBD as a potential novel treatment for psychotic disorders.They concluded that CBD represents a promising potential novel treatment for patients with psychosis. It also appears that CBD may improve the disease trajectory of individuals with early psychosis and comorbid cannabis misuse.13 CBD use has also been associated with a decrease in symptoms of psychosis and changes in brain activity during verbal memory tasks in patients at high risk of psychosis.6 However, before CBD can become a viable treatment option for psychosis, the promising findings in these initial clinical studies must be replicated in large-scale trials with appropriate treatment duration.

Pages

Recommended Reading

The psychiatric clinic of the future
MDedge Psychiatry
Command hallucinations, but is it really psychosis?
MDedge Psychiatry
Is psychosis toxic to the brain?
MDedge Psychiatry
The ABCDs of treating tardive dyskinesia
MDedge Psychiatry
First-in-class schizophrenia drug safe, effective, durable
MDedge Psychiatry
Drive-up pharmacotherapy during the COVID-19 pandemic
MDedge Psychiatry
Time to retire haloperidol?
MDedge Psychiatry
Anti-NMDAR encephalitis or primary psychiatric disorder?
MDedge Psychiatry
New ‘atlas’ maps links between mental disorders, physical illnesses
MDedge Psychiatry
Planning for a psychiatric COVID-19–positive unit
MDedge Psychiatry